152 related articles for article (PubMed ID: 18166465)
1. Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.
Gediya LK; Belosay A; Khandelwal A; Purushottamachar P; Njar VC
Bioorg Med Chem; 2008 Mar; 16(6):3352-60. PubMed ID: 18166465
[TBL] [Abstract][Full Text] [Related]
2. MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours.
Khandelwal A; Gediya L; Njar V
Br J Cancer; 2008 Apr; 98(7):1234-43. PubMed ID: 18349838
[TBL] [Abstract][Full Text] [Related]
3. Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.
Patel JB; Mehta J; Belosay A; Sabnis G; Khandelwal A; Brodie AM; Soprano DR; Njar VC
Br J Cancer; 2007 Apr; 96(8):1204-15. PubMed ID: 17387344
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice.
Huynh CK; Brodie AM; Njar VC
Br J Cancer; 2006 Feb; 94(4):513-23. PubMed ID: 16449997
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
Wang XF; Qian DZ; Ren M; Kato Y; Wei Y; Zhang L; Fansler Z; Clark D; Nakanishi O; Pili R
Clin Cancer Res; 2005 May; 11(9):3535-42. PubMed ID: 15867257
[TBL] [Abstract][Full Text] [Related]
6. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
Patel JB; Huynh CK; Handratta VD; Gediya LK; Brodie AM; Goloubeva OG; Clement OO; Nanne IP; Soprano DR; Njar VC
J Med Chem; 2004 Dec; 47(27):6716-29. PubMed ID: 15615521
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors promote osteoblast maturation.
Schroeder TM; Westendorf JJ
J Bone Miner Res; 2005 Dec; 20(12):2254-63. PubMed ID: 16294278
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells.
Noack K; Mahendrarajah N; Hennig D; Schmidt L; Grebien F; Hildebrand D; Christmann M; Kaina B; Sellmer A; Mahboobi S; Kubatzky K; Heinzel T; Krämer OH
Arch Toxicol; 2017 May; 91(5):2191-2208. PubMed ID: 27807597
[TBL] [Abstract][Full Text] [Related]
9. In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.
Qian DZ; Ren M; Wei Y; Wang X; van de Geijn F; Rasmussen C; Nakanishi O; Sacchi N; Pili R
Prostate; 2005 Jun; 64(1):20-8. PubMed ID: 15651062
[TBL] [Abstract][Full Text] [Related]
10. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
[TBL] [Abstract][Full Text] [Related]
11. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis.
Pili R; Kruszewski MP; Hager BW; Lantz J; Carducci MA
Cancer Res; 2001 Feb; 61(4):1477-85. PubMed ID: 11245454
[TBL] [Abstract][Full Text] [Related]
12. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Touma SE; Goldberg JS; Moench P; Guo X; Tickoo SK; Gudas LJ; Nanus DM
Clin Cancer Res; 2005 May; 11(9):3558-66. PubMed ID: 15867260
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
Qian DZ; Wei YF; Wang X; Kato Y; Cheng L; Pili R
Prostate; 2007 Aug; 67(11):1182-93. PubMed ID: 17520666
[TBL] [Abstract][Full Text] [Related]
14. A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells.
Gediya LK; Chopra P; Purushottamachar P; Maheshwari N; Njar VC
J Med Chem; 2005 Jul; 48(15):5047-51. PubMed ID: 16033284
[TBL] [Abstract][Full Text] [Related]
15. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS
Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
[TBL] [Abstract][Full Text] [Related]
16. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
[TBL] [Abstract][Full Text] [Related]
17. Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
Nidhyanandan S; Thippeswamy BS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Karthikeyan K; Khan FR; Raghul J; Vijaykanth G; Narayanan S
Anticancer Drugs; 2017 Oct; 28(9):1002-1017. PubMed ID: 28727579
[TBL] [Abstract][Full Text] [Related]
18. Class IIb HDAC Inhibition Enhances the Inhibitory Effect of Am80, a Synthetic Retinoid, in Prostate Cancer.
Ishigami-Yuasa M; Ekimoto H; Kagechika H
Biol Pharm Bull; 2019; 42(3):448-452. PubMed ID: 30828077
[TBL] [Abstract][Full Text] [Related]
19. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
20. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
